Zoetis (ZTS) Q4 FY25 earnings call: guidance and Q&A

How is competition factored into 2026 guidance, especially for key derm given Q4 moderation? What are the price vs. volume assumptions for next year?

Management expects competition, including aggressive promotional activity, to continue and is factored into the guidance. They anticipate returning to a normal price range of 2-3%, with the balance from volume.

“On price, we've said we would return to our normal rate range, which is 2% to 3%, which is what you can assume in this guidance with the balance, of course, being volume.”

asked by Michael Ryskin · answered by Wetteny Joseph

What U.S. companion animal operational growth is incorporated in the 3-5% guidance? What is the impact of the 1-month lag fixing on 2026 revenue? How is organic operational growth defined?

The guidance considers current market conditions and the company's strong portfolio. The 1-month lag change for international subsidiaries is being implemented in Q1 2026, and recast financials will be provided for comparability. Organic operational growth excludes FX and significant (>=1% of prior year revenue) acquisitions/divestitures.

“OOG definition is something we thought we would have a basis or a metric that is very consistent for our analysts and investors to be able to gauge us on. And so what we're doing here is sustaining that metric versus bringing it in and out intermittently.”

asked by Erin Wilson Wright · answered by Wetteny Joseph

How should investors think about the sequential quarterly growth for 2026 given accounting changes, competition, and comps? Is the pet owner financial situation worsening, or are vet clinics adjusting pricing?

Q1/H1 2026 will face tougher comps due to strong H1 2025 performance and the timing of OA pain product impacts. Competitive launch aggression might extend. Pet owners are price sensitive, but demand for animal health remains high, with vets adjusting pricing and offering value.

“I think there was really just pricing at the vet clinic was taken a lot over the last 3 years. And I think the view from the pet owners is it was a little much.”

asked by Brandon Vazquez · answered by Wetteny Joseph

How will Zoetis drive volume vs. price in 2026, given prior years' price-driven revenue? Are there changes in pricing strategy, especially for innovation vs. in-line products?

Zoetis's pricing approach remains consistent: product-by-product, market-by-market, based on clinical value. They leverage their broad portfolio to drive volumes where legally allowed, and this strategy will continue with new innovations.

“Our pricing has always been and remains an element that we take into consideration, product by product, market by market, and the value -- the clinical value we bring, both to vet and pet owners through those products.”

asked by David Westenberg · answered by Wetteny Joseph

Will 2026 revenues benefit from the accounting adjustment, specifically an extra month of international sales due to the fiscal year alignment?

There will not be an "extra month" of sales. The fiscal year alignment, once implemented, will result in a 12-month year from January to December. Recast financials will be provided for prior periods to ensure comparability.

“there is not an extra month that we would contemplate. Again, we have not implemented fiscal year alignment. I want to make sure that is very clear.”

asked by Jon Block · answered by Wetteny Joseph

What are the derm market growth assumptions for 2026 and how do they influence guidance? When do key patents for Simparica and Apoquel expire?

Derm is expected to contribute to growth, with key franchises leading the way for mid- to high single-digit growth. Apoquel's patent expires around 2032.

“for example, with Apoquel, we're out to 2032 time frame on that in terms of what our patent expires on that”

asked by Daniel Clark · answered by Wetteny Joseph